"Training in Neuroimmune/Neurobehavior Addiction Research"
Training Grant Directors:
Tom Molitor, Ph.D.
Sabita Roy, Ph.D.
For both predoctoral and postdoctoral trainees: U.S. citizen and those foreign nationals who possess a permanent residency.
Predoctoral Trainees: Predoctoral candidates must have earned a bachelor degree and be accepted into the University of Minnesota Graduate Program and interested in interdisciplinary aspects of addiction-related research.
Postdoctoral Trainees: Postdoctoral candidates must have a PhD, DVM, or MD and be interested in laboratory-based Neuroimmune/Neurobehavior Addiction Research
To train biomedical scientists at the pre- and post-doctoral levels in an interdisciplinary field that focuses on the interactions of drugs of abuse with the nervous and immune systems, and integrates our understanding of these physiological interactions with their behavioral counterparts.
The PNI program focuses on the training of pre- and post-doctoral fellows in areas that intersect four disciplines: Pharmacology, Psychology/Psychiatry, Neuroscience, and Microbiology/Immunology. Trainees are committed to a research in the field of Neuroimmune/Neurobehavior Addiction Research, which emphasizes the effects of drug abuse.
Application materials are accepted throughout the year until all the slots are filled. Qualified candidate must submit following materials to Program Administrator via email.
1. PNI Application form
2. Curriculum Vitae
3. Official transcripts for both (non-University of Minnesota) undegraduate and graduate course work
4. Three letters of recommendation
Once all the materials have been received by the Program Administrator, our selection committee will review the materials and make decisions based on the candidates' productivity, research goals and experience. This process will take up to four weeks.
|Gavin Bart, MD||Medicine (Pharmacology)||Opiate dependence and human pharmacology|
|Alvin J. Beitz, PhD
|Veterinary and Biomedical Sciences||Mechanisms underlying chronic pain conditions and the role of inflammation|
|David R. Brown, PhD
|Veterinary and Biomedical Sciences||Drugs of Abuse and Mucosal Immune Function|
|Marilyn E. Carroll, PhD
|Psychiatry (Neuroscience)||Vulnerability to drug abuse, animal models, phases of drug abuse, and treatment approaches.|
|Maxim C.J. Cheeran, PhD||Veterinary Population Medicine||Neuroimmune response to viral infections of the CNS|
|William C. Engeland, PhD
|Neuroscience||Neuroendocrinology of Stress|
|Carolyn A. Fairbanks, PhD
|Pharmaceutics (Pharmacology, Neuroscience)||Endogenous control of the neuroadaptation of pain, opioid tolerance and addiction|
|Jonathan C. Gewirtz, PhD
|Psychology (Neuroscience)||Negative affect and drug dependence|
|Andrew C. Harris, PhD||Medicine||Preclinical Behavioral Models of Drug Addiction|
|Dorothy K. Hatsukami, PhD
|Christopher N. Honda, PhD
|Neuroscience||Neural-immune Interactions in Peripheral Analgesia|
|Alice A. Larson, PhD||Veterinary and Biomedical Sciences||Mechanism of pain transmission, especially with respect to musculoskeletal pain of fibromyalgia|
|Mark LeSage, PhD||Medicine||Behavioral Pharmacology of Stimulants, Immunotherapy for Drug Abuse|
|Allen S. Levine, PhD||
Food Science & Nutrition (CFANS)
|Neuroregulation of food intake|
|Kelvin O. Lim, MD||Psychiatry||Neuroimaging of cocaine dependence|
|James R. Lokensgard, PhD
|Walter C. Low, PhD||Neurosurgery (Integrative Biology and Physiology)||Neural regeneration, stem cells, gene therapy, and antiapoptotic agents|
|Louis M. Mansky, PhD||Institute for Molecular Virology, Diagnostics & Biological Sciences (Microbiology)||Molecular and cell biology of HIV and HTLV|
|Jonathan Marchant, PhD||Pharmacology||Modulation of cellular calcium signaling|
|Thomas W. Molitor, PhD||Veterinary Population Medicine||Opioid drug abuse and immune system/infectious disease interactions|
|Michael P. Murtaugh, PhD
||Veterinary and Biomedical Sciences||Host response and immunity to infection|
|J. Bruce Overmier, PhD
||Psychology (Neuroscience, Cognitive Science)||Stress and Learning|
|Jose V. Pardo, MD, PhD
||Psychiatry||Neuroimaging of Aging & Fibromyalgia|
|Paul R. Pentel, MD
|Medicine (Pharmacology)||Pharmacokinetic approaches to addiction treatment|
|Phillip K. Peterson, MD
||Medicine||Host defenses and pathogenesis of central nervous system infections.|
|Philip S. Portoghese, PhD
||Medicinal Chemistry (Pharmacology, Neuroscience)||Opioid and chemokine receptors|
|Marco Pravetoni, PhD||Medicine||Prescription opioid abuse|
|Sundaram, Ramakrishnan, PhD||Pharmacology (Medical School)||Endothelial biology and angiogenesis|
|R. Bryan Rock, MD||Medicine||Central Nervous System Infections|
|Sabita Roy, PhD
||Surgery (Pharmacology)||Opioid drug abuse and immune modulation|
|Ashok K.Saluja, PhD||Surgery (Pharmacology)||Pancreatitis and pancreatic cancer|
|Pamela J. Skinner, PhD||Veterinary and Biomedical Sciences||Prion diseases and HIV pathogenesis and treatment|
|Srinand Sreevatsan, PhD||Veterinary Population Medicine (Veterinary and Biomedical Sciences)||Microbe-host interactions|
|Stanley A. Thayer, PhD
||Pharmacology||Pharmacological Regulation of HIV Neurotoxicity|
|Lucy Vulchanova, PhD||Veterinary and Biomedical Sciences||Neuroimmune interactions in pain mechanisms|
|Kevin D. Wickman, PhD
||Pharmacology||Neuronal G protein signaling and complex behavior|
|George L. Wilcox, PhD
||Neuroscience (Pharmacology, Dermatology)||Opioid use in chronic pain; mechanism of synergistic interactions between spinal analgesics; microglial activation metabolomics; anti-glutamatergic neuromodulation of opioid tolerance and addiction.|